Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status

Rybrevant + chemo shows improved OS data in NSCLC

Updated results from the phase III MARIPOSA-2 study showed Rybrevant (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated NSCLC with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations.

September 20, 2024

Vol.50 No.35

Drugs & Targets

FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations

FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Friends publishes evaluation of RWE in NSCLC

Findings by Friends of Cancer Research were published recently in JCO Clinical Cancer Informatics in a paper titled “Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy.”

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approved Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

September 06, 2024

Vol.50 No.33

Drugs & Targets

FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC

FDA approved durvalumab (Imfinzi) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial

Genentech, a member of the Roche Group, announced that the phase II/III SKYSCRAPER-06 study evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival at its primary analysis with a hazard ratio of 1.27 [95% CI: 1.02,1.57] and overall survival at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature.

July 12, 2024

Vol.50 No.28

Phase III Tecentriq Study Shows Better Survival vs. Chemo Regardless of PD-L1 Status

YOU MAY BE INTERESTED IN

Rybrevant + chemo shows improved OS data in NSCLC

FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations

Friends publishes evaluation of RWE in NSCLC

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC

Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login